United States Biotechnology & Medical Research

NRX Pharmaceuticals Inc (NRXP)

Track

Track

The most recent insider activity at NRX Pharmaceuticals Inc occurred on December 17, 2024, when Chairman and Chief Scientist Jonathan C. Javitt purchased 40,000 shares. This transaction represents the only recorded movement within the last three months, following a series of historical acquisitions by various company officials dating back to 2022.
Ticker: NRXP Exchange: NAS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
No insider activity signals detected

Insider trades have not triggered unusual activity signals for this company.

Top insiders
Trades
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
3.3
Javitt Jonathan C Chairman and Chief Scientist Executive Director Large shareholder
Transaction date
Purchase
Price
403.37
Quantity 71,121 +1.5%
Value US$1,505,919
2.2
Gorovitz Aaron Non-Executive Director
Transaction date
Purchase
Price
425.84
Quantity 68,745 +17.1%
Value US$1,510,342
2.4
Hurvitz Chaim Non-Executive Director
Transaction date
Purchase
Price
106.88
Quantity 30,628 -9.8%
Value US$119,595
3.3
Javitt Jonathan C Chief Scientist Executive Director Large shareholder
Transaction date
Purchase
Price
0.33
Quantity 100,000 +28.9%
Value US$33,000
3.3
Javitt Jonathan C Chief Scientist Executive Director Large shareholder
Transaction date
Purchase
Price
0.32
Quantity 200,000 +136.7%
Value US$64,400
1.4
Willard Stephen H CHIEF EXECUTIVE OFFICER Executive Director
Transaction date
Purchase
Price
1.17
Quantity 50,000 +inf%
Value US$58,500
1.7
VAN VOORHEES SETH CHIEF FINANCIAL OFFICER Officer
Transaction date
Purchase
Price
1.10
Quantity 30,000 +183.6%
Value US$33,000
3.3
Javitt Jonathan C Non-Executive Director Large shareholder
Transaction date
Sale
Price
1.00
Quantity 400,000 -3.0%
Value US$400,000
2.7
Javitt Daniel C. Large shareholder
Transaction date
Planned sale
Price
1.50
Quantity 8,441 -0.1%
Value US$12,700
2.7
Javitt Daniel C. Large shareholder
Transaction date
Planned sale
Price
1.50
Quantity 13,730 -0.1%
Value US$20,651
0.6
Flynn Patrick John Non-Executive Director
Transaction date
Purchase
Price
1.25
Quantity 1,750 +inf%
Value US$2,188
0.6
Flynn Patrick John Non-Executive Director
Transaction date
Purchase
Price
1.24
Quantity 2,500 +6.6%
Value US$3,100
0.6
Flynn Patrick John Non-Executive Director
Transaction date
Purchase
Price
1.25
Quantity 2,500 +7.1%
Value US$3,125
0.6
Flynn Patrick John Non-Executive Director
Transaction date
Purchase
Price
1.25
Quantity 2,500 +6.6%
Value US$3,125
0.6
Flynn Patrick John Non-Executive Director
Transaction date
Purchase
Price
1.25
Quantity 2,500 +7.1%
Value US$3,125
1.7
VAN VOORHEES SETH CHIEF FINANCIAL OFFICER Officer
Transaction date
Purchase
Price
1.11
Quantity 7,021 +75.0%
Value US$7,793
1.7
VAN VOORHEES SETH CHIEF FINANCIAL OFFICER Officer
Transaction date
Purchase
Price
1.10
Quantity 600 +6.9%
Value US$660
1.7
VAN VOORHEES SETH CHIEF FINANCIAL OFFICER Officer
Transaction date
Purchase
Price
1.12
Quantity 8,716 +inf%
Value US$9,762
2.4
Hurvitz Chaim Non-Executive Director
Transaction date
Purchase
Price
1.10
Quantity 40,408 +8.8%
Value US$44,449
2.4
Hurvitz Chaim Non-Executive Director
Transaction date
Purchase
Price
1.08
Quantity 171,780 +59.7%
Value US$185,522
2.7
Javitt Daniel C. Large shareholder
Transaction date
Planned sale
Price
1.05
Quantity 33,018 -0.3%
Value US$34,745
2.4
Hurvitz Chaim Non-Executive Director
Transaction date
Purchase
Price
0.99
Quantity 287,812 +inf%
Value US$284,934
2.7
Javitt Daniel C. Large shareholder
Transaction date
Planned sale
Price
1.02
Quantity 133,719 -1.4%
Value US$136,393
2.7
Javitt Daniel C. Large shareholder
Transaction date
Planned sale
Price
1.01
Quantity 49,200 -0.5%
Value US$49,510
2.7
Javitt Daniel C. Large shareholder
Transaction date
Sale
Price
1.01
Quantity 784,063 -7.4%
Value US$791,433
2.7
Javitt Daniel C. Large shareholder
Transaction date
Sale
Price
0.65
Quantity 86,459 -0.7%
Value US$55,861
2.7
Javitt Daniel C. Large shareholder
Transaction date
Sale
Price
0.67
Quantity 115,657 -0.9%
Value US$76,947
2.7
Javitt Daniel C. Large shareholder
Transaction date
Sale
Price
0.70
Quantity 243,596 -1.9%
Value US$171,102
3.3
Javitt Jonathan C Chief Scientist Executive Director Large shareholder
Transaction date
Purchase
Price
58.00
Quantity 100,000 +215.8%
Value US$5,800,000
3.3
Besthof Robert Chief Comm. & Patient Officer Officer
Transaction date
Sale
Price
11.76
Quantity 40,000 -62.8%
Value US$470,400
3.3
Daigneault Alessandra General Counsel & Secretary Officer
Transaction date
Sale
Price
13.11
Quantity 33,715 -100.0%
Value US$442,004
ACKERMAN RICHARD President and CEO
Transaction date
Sale
Price
0.00
Quantity 1,500,000
Value US$0
ACKERMAN RICHARD President and CEO
Transaction date
Purchase
Price
10.00
Quantity 22,500 +9.0%
Value US$225,000
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2024-12-18 2024-12-17 B Purchase
3.3
Javitt Jonathan C

Chairman and Chief Scientist

Executive Director Large shareholder
71,121 +1.5%
403.37
US$1,505,919 		71,121 +1.5% 403.37 US$1,505,919
2023-09-11 2023-08-30 B Purchase
2.2
Gorovitz Aaron
Non-Executive Director
68,745 +17.1%
425.84
US$1,510,342 		68,745 +17.1% 425.84 US$1,510,342
2023-09-11 2023-08-30 B Purchase
2.4
Hurvitz Chaim
Non-Executive Director
30,628 -9.8%
106.88
US$119,595 		30,628 -9.8% 106.88 US$119,595
2023-08-24 2023-08-23 B Purchase
3.3
Javitt Jonathan C

Chief Scientist

Executive Director Large shareholder
100,000 +28.9%
0.33
US$33,000 		100,000 +28.9% 0.33 US$33,000
2023-08-23 2023-08-22 B Purchase
3.3
Javitt Jonathan C

Chief Scientist

Executive Director Large shareholder
200,000 +136.7%
0.32
US$64,400 		200,000 +136.7% 0.32 US$64,400
2022-12-19 2022-12-16 B Purchase
1.4
Willard Stephen H

CHIEF EXECUTIVE OFFICER

Executive Director
50,000 +inf%
1.17
US$58,500 		50,000 +inf% 1.17 US$58,500
2022-12-19 2022-12-16 B Purchase
1.7
VAN VOORHEES SETH

CHIEF FINANCIAL OFFICER

Officer
30,000 +183.6%
1.10
US$33,000 		30,000 +183.6% 1.10 US$33,000
2022-12-09 2022-12-07 S Sale
3.3
Javitt Jonathan C
Non-Executive Director Large shareholder
400,000 -3.0%
1.00
US$400,000 		400,000 -3.0% 1.00 US$400,000
2022-12-01 2022-11-30 PlS Planned sale
2.7
Javitt Daniel C.
Large shareholder
8,441 -0.1%
1.50
US$12,700 		8,441 -0.1% 1.50 US$12,700
2022-12-01 2022-11-29 PlS Planned sale
2.7
Javitt Daniel C.
Large shareholder
13,730 -0.1%
1.50
US$20,651 		13,730 -0.1% 1.50 US$20,651
2022-11-29 2022-11-28 B Purchase
0.6
Flynn Patrick John
Non-Executive Director
1,750 +inf%
1.25
US$2,188 		1,750 +inf% 1.25 US$2,188
2022-11-29 2022-11-28 B Purchase
0.6
Flynn Patrick John
Non-Executive Director
2,500 +6.6%
1.24
US$3,100 		2,500 +6.6% 1.24 US$3,100
2022-11-29 2022-11-28 B Purchase
0.6
Flynn Patrick John
Non-Executive Director
2,500 +7.1%
1.25
US$3,125 		2,500 +7.1% 1.25 US$3,125
2022-11-29 2022-11-28 B Purchase
0.6
Flynn Patrick John
Non-Executive Director
2,500 +6.6%
1.25
US$3,125 		2,500 +6.6% 1.25 US$3,125
2022-11-29 2022-11-28 B Purchase
0.6
Flynn Patrick John
Non-Executive Director
2,500 +7.1%
1.25
US$3,125 		2,500 +7.1% 1.25 US$3,125
2022-11-28 2022-11-25 B Purchase
1.7
VAN VOORHEES SETH

CHIEF FINANCIAL OFFICER

Officer
7,021 +75.0%
1.11
US$7,793 		7,021 +75.0% 1.11 US$7,793
2022-11-28 2022-11-25 B Purchase
1.7
VAN VOORHEES SETH

CHIEF FINANCIAL OFFICER

Officer
600 +6.9%
1.10
US$660 		600 +6.9% 1.10 US$660
2022-11-28 2022-11-25 B Purchase
1.7
VAN VOORHEES SETH

CHIEF FINANCIAL OFFICER

Officer
8,716 +inf%
1.12
US$9,762 		8,716 +inf% 1.12 US$9,762
2022-11-21 2022-11-18 B Purchase
2.4
Hurvitz Chaim
Non-Executive Director
40,408 +8.8%
1.10
US$44,449 		40,408 +8.8% 1.10 US$44,449
2022-11-21 2022-11-17 B Purchase
2.4
Hurvitz Chaim
Non-Executive Director
171,780 +59.7%
1.08
US$185,522 		171,780 +59.7% 1.08 US$185,522
2022-11-18 2022-11-17 PlS Planned sale
2.7
Javitt Daniel C.
Large shareholder
33,018 -0.3%
1.05
US$34,745 		33,018 -0.3% 1.05 US$34,745
2022-11-21 2022-11-16 B Purchase
2.4
Hurvitz Chaim
Non-Executive Director
287,812 +inf%
0.99
US$284,934 		287,812 +inf% 0.99 US$284,934
2022-11-18 2022-11-16 PlS Planned sale
2.7
Javitt Daniel C.
Large shareholder
133,719 -1.4%
1.02
US$136,393 		133,719 -1.4% 1.02 US$136,393
2022-11-15 2022-11-11 PlS Planned sale
2.7
Javitt Daniel C.
Large shareholder
49,200 -0.5%
1.01
US$49,510 		49,200 -0.5% 1.01 US$49,510
2022-08-02 2022-07-29 S Sale
2.7
Javitt Daniel C.
Large shareholder
784,063 -7.4%
1.01
US$791,433 		784,063 -7.4% 1.01 US$791,433
2022-06-07 2022-06-07 S Sale
2.7
Javitt Daniel C.
Large shareholder
86,459 -0.7%
0.65
US$55,861 		86,459 -0.7% 0.65 US$55,861
2022-06-07 2022-06-06 S Sale
2.7
Javitt Daniel C.
Large shareholder
115,657 -0.9%
0.67
US$76,947 		115,657 -0.9% 0.67 US$76,947
2022-06-07 2022-06-03 S Sale
2.7
Javitt Daniel C.
Large shareholder
243,596 -1.9%
0.70
US$171,102 		243,596 -1.9% 0.70 US$171,102
2022-06-02 2022-06-01 B Purchase
3.3
Javitt Jonathan C

Chief Scientist

Executive Director Large shareholder
100,000 +215.8%
58.00
US$5,800,000 		100,000 +215.8% 58.00 US$5,800,000
2021-11-02 2021-09-15 S Sale
3.3
Besthof Robert

Chief Comm. & Patient Officer

Officer
40,000 -62.8%
11.76
US$470,400 		40,000 -62.8% 11.76 US$470,400
2021-11-02 2021-08-23 S Sale
3.3
Daigneault Alessandra

General Counsel & Secretary

Officer
33,715 -100.0%
13.11
US$442,004 		33,715 -100.0% 13.11 US$442,004
2020-03-17 2020-03-13 S Sale
2.3
Polar Asset Management Partners Inc.
Large shareholder
29,464 -5.7%
10.60
US$312,318 		29,464 -5.7% 10.60 US$312,318
2018-11-20 2018-11-20 S Sale ACKERMAN RICHARD

President and CEO
1,500,000
0.00
US$0 		1,500,000 0.00 US$0
2017-12-04 2017-11-29 B Purchase ACKERMAN RICHARD

President and CEO
22,500 +9.0%
10.00
US$225,000 		22,500 +9.0% 10.00 US$225,000
Explore more

More insider trading research around NRX Pharmaceuticals Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America